Evidence map›Paper›PMID 39294825›Full record

ArticleBiomarker research2024

Tumor endothelium-derived PODXL correlates with immunosuppressive microenvironment and poor prognosis in cervical cancer patients receiving radiotherapy or chemoradiotherapy.

Rui Huang, Fuhao Wang, Wenxue Zou, Xiaohui Li, Tianyu Lei, Peihang Li, Yajun Song, Chao Liu, Jinbo Yue

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rui Huang *Department of Oncology, Chongqing University Fuling Hospital, Chongqing, China.
Fuhao Wang *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical Universityand, Shandong Academy of Medical Sciences , Jinan, China.
Wenxue Zou *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical Universityand, Shandong Academy of Medical Sciences , Jinan, China.
Xiaohui LiDepartment of Medical Oncology, Peking University First Hospital, Beijing, China.
Tianyu LeiDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Peihang LiDepartment of Radiation Oncology, Tianjin Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yajun SongDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical Universityand, Shandong Academy of Medical Sciences , Jinan, China.
Chao LiuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical Universityand, Shandong Academy of Medical Sciences , Jinan, China. charles.liu@whu.edu.cn.ORCID http://orcid.org/0000-0002-3807-9901
Jinbo YueDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical Universityand, Shandong Academy of Medical Sciences , Jinan, China. jbyue@sdfmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Podocalyxin-like protein (PODXL) is known to originate from tumor cells in several cancers; however, which cell type it is expressed in, whether and how it may contribute to tumor progression after radiotherapy or chemoradiotherapy in cervical cancer (CC) remain unknown. In this study, we investigated these issues using a cohort of 180 immune stain data, single-cell RNA sequencing (scRNA-seq) data of 29,453 cells, and bulk RNA sequencing data from 187 cervical cancer samples treated with radiotherapy or chemoradiotherapy. ScRNA-seq analysis revealed that PODXL was predominantly expressed in tumor endothelial cells (TECs) of CC, which was corroborated by tumor section staining. Moreover, the PODXL expression level was negatively associated with progression-free survival and overall survival of 180 CC patients receiving radiotherapy or chemoradiotherapy (both p < 0.001). Furthermore, compared with PODXL

Indexed as

Cervical cancerChemoradiotherapyImmune responsePrognosis

Identifiers

PMID39294825
PMCPMC11409751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.